Mutual Funds
Mutual Funds
Fund Profile
Scheme Profile
Daily NAV
Historical NAV
Category Returns
Dividend Details
Fund Ranking
MF Activities
All Holdings
What's In / What's Out
MF Trends
MF Tools
  Home   >   MUTUAL FUND  >  MUTUAL FUNDS  > SCHEME PROFILE
SCHEME PROFILE      
AMC : Category : Scheme :
Nippon India Pharma Fund(G)-Direct Plan
TypeInvestment In% of NAVNo. of sharesValue (Rs cr)
Domestic EquitiesSun Pharmaceutical Industries Limited12.566462563491049.5651
Domestic EquitiesDivi's Laboratories Limited9.49041198808792.6518
Domestic EquitiesLupin Limited5.82232483991486.2909
Domestic EquitiesCipla Limited5.61563200000469.0240
Domestic EquitiesDr. Reddy's Laboratories Limited5.48613662170458.2107
Domestic EquitiesApollo Hospitals Enterprise Limited5.3448648795446.4034
Domestic EquitiesMedPlus Health Services Limited4.19703627277350.5400
Domestic EquitiesGlaxoSmithKline Pharmaceuticals Limited3.7272943731311.2991
Domestic EquitiesVijaya Diagnostic Centre Limited3.24212831564270.7825
Domestic EquitiesNarayana Hrudayalaya Limited2.93761406946245.3573
Domestic EquitiesGland Pharma Limited2.90891529352242.9529
Domestic EquitiesAjanta Pharma Limited2.8839959323240.8668
Domestic EquitiesAbbott India Limited2.868878677239.6108
Domestic EquitiesDr. Lal Path Labs Limited2.3659709112197.6011
Domestic EquitiesAurobindo Pharma Limited2.33981702630195.4279
Domestic EquitiesMankind Pharma Limited2.2381757496186.9273
Domestic EquitiesZydus Lifesciences Limited2.22772000632186.0588
Domestic EquitiesThyrocare Technologies Limited2.21821765838185.2717
Domestic EquitiesPfizer Limited2.1389318249178.6427
Domestic EquitiesJB Chemicals & Pharmaceuticals Limited2.0063999649167.5712
Domestic EquitiesAlkem Laboratories Limited1.9759323678165.0272
Domestic EquitiesSanofi India Limited1.7073230272142.5959
Domestic EquitiesSai Life Sciences Limited1.40041545179116.9623
Domestic EquitiesSanofi Consumer Healthcare India Limited1.3478213659112.5684
Domestic EquitiesIPCA Laboratories Limited1.3398785412111.9055
Domestic EquitiesSuraksha Diagnostic Limited1.21863169618101.7764
Domestic EquitiesTorrent Pharmaceuticals Limited1.153130336496.3090
Domestic EquitiesFortis Healthcare Limited0.9335110388977.9677
Domestic EquitiesBiocon Limited0.9185228422276.7156
Domestic EquitiesSyngene International Limited0.8707112479572.7236
Domestic EquitiesEmcure Pharmaceuticals Limited0.748847027262.5415
Domestic EquitiesAstraZeneca Pharma India Limited0.61166407851.0830
Domestic EquitiesAkums Drugs and Pharmaceuticals Limited0.570483371847.6386
Domestic EquitiesIndoco Remedies Limited0.5507183492445.9979
Domestic EquitiesOrchid Pharma Limited0.370949272730.9802
Domestic EquitiesConcord Biotech Limited0.233911173819.5374
Total 98.5779 8233.3862
Cash & Cash Equivalents and Net AssetsTriparty Repo1.5241 127.2964
Cash & Cash Equivalents and Net AssetsCash Margin - CCIL0.0007 0.0621
Cash & Cash Equivalents and Net AssetsNet Current Assets-0.1027 -8.5803
Total 1.4221 118.7782
 
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.